FDG-PET/CT useful in evaluating response to melanoma drugs

01/11/2012 | AuntMinnie.com (free registration)

Patients with melanoma who had partial metabolic response to bevacizumab plus ipilimumab, determined through FDG-PET/CT scans, had longer disease-free survival compared with patients who had stable or progressive metabolic disease, according to Dana-Farber Cancer Institute researchers. "While the results are preliminary and further studies are needed, these results suggest both contrast-enhanced CT and FDG-PET may be important imaging biomarkers of efficacy for these therapeutic targets in this clinical setting," said researcher Dr. Pamela DiPiro.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC